Top

Drug Safety

Published in:

01-02-2009 | Practical Drug Safety

Treating Hypertension in Older Adults

Safety Considerations

Author: Dr Wilbert S. Aronow

Published in: Drug Safety | Issue 2/2009

Abstract

This article discusses the efficacy, use and adverse effects of antihypertensive drug therapy in older adults. Numerous double-blind, randomized, placebo-controlled studies have demonstrated that antihypertensive drug therapy reduces cardiovascular events in older adults. All antihypertensive drugs may predispose older patients to the development of symptomatic orthostatic hypotension and postprandial hypotension, and syncope or falls. Adverse effects of diuretics, β-adrenergic receptor antagonists, ACE inhibitors, angiotensin receptor antagonists, calcium channel antagonists, α-adrenergic receptor antagonists, centrally acting drugs and direct vasodilators are discussed. The adverse effects depend on the antihypertensive drugs used, the doses used, the co-morbidities present in older patients taking these drugs and drug-drug interactions.

Aronow WS, Ahn C, Kronzon I, et al. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 1991; 67: 295–9PubMedCrossRef

Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996; 77: 864–6PubMedCrossRef

Vokonas PS, Kannel WB. Epidemiology of coronary heart disease in the elderly. In: Aronow WS, Fleg JL, Rich MW editors. Cardiovascular disease in the elderly. 4th ed. New York: Informa Healthcare, 2008: 215–41CrossRef

Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women. Am J Cardiol 1996; 77: 1381–3PubMedCrossRef

Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep 2004; 6: 124–9PubMedCrossRef

Wolf PA. Cerebrovascular disease in the elderly. In: Tresch DD, Aronow WS, editors. Cardiovascular disease in the elderly patient. New York: Marcel Dekker, 1994: 125–47

Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol 1999; 84: 611–2PubMedCrossRef

Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–62PubMedCrossRef

Stokes III J, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987; 75 (6 Pt 2): V65–73PubMed

10.

Aronow WS, Sales FF, Etienne F, et al. Prevalence of peripheral arterial disease and its correlation with risk factors for peripheral arterial disease in elderly patients in a longterm health care facility. Am J Cardiol 1988; 62: 644–6PubMedCrossRef

11.

Ness J, Aronow WS, Ahn C. Risk factors for peripheral arterial disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc 2000; 48: 312–14PubMed

12.

Ness J, Aronow WS, Newkirk E, et al. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol Med Sci 2005; 60A: M255–7CrossRef

13.

Morley JE, Rich MW. Disability and frailty in older patients with cardiovascular disease. In: Aronow WS, Fleg JL, Rich MW editors. Cardiovascular disease in the elderly. 4th ed. New York: Informa Healthcare, 2008: 811–8CrossRef

14.

Hajjar I, Miller K, Hirth V. Age-related bias in the management of hypertension: a national survey of physicians opinions on hypertension in elderly adults. J Gerontol Med Sci 2002; 57A: M487–91CrossRef

15.

Goodwin JS. Embracing complexity: a consideration of hypertension in the very old. J Gerontol Med Sci 2003; 58A: M653–8CrossRef

16.

Hajjar RR. Commentary on Goodwin JS. Embracing complexity: a consideration of hypertension in the very old. J Gerontol Med Sci 2003; 58A: M661CrossRef

17.

Aronow WS, Frishman WH. Effect of antihypertensive drug treatment on cognitive function. Clin Geriatr 2006; 14(11): 25–8

18.

Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind hypertension trial. SCOPE Study Group. J Hypertens 2003; 21: 875–86PubMedCrossRef

19.

Gandelman G, Aronow WS, Varma R. Prevalence of adequate blood pressure control in self-pay or Medicare patients versus Medicaid or private insurance patients with systemic hypertension followed in a university cardiology or general medicine clinic. Am J Cardiol 2004; 94: 815–6PubMedCrossRef

20.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–72PubMedCrossRef

21.

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98PubMedCrossRef

22.

Mendelson G, Ness J, Aronow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 597–9PubMed

23.

Koka M, Joseph J, Aronow WS. Adequacy of control of hypertension in an academic nursing home. J Am Med Dir Assoc 2007; 8: 538–40PubMedCrossRef

24.

Mendelson G, Nassimiha D, Aronow WS. Simultaneous measurements of blood pressures in right and left brachial arteries. Cardiol Rev 2004; 12: 276–8PubMedCrossRef

25.

Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol 2008; 124: 6–21PubMedCrossRef

26.

Aronow WS. Dizziness and syncope. In: Hazzard WR, Blass JP, Ettinger Jr WH, et al., editors. Principles of geriatric medicine and gerontology. 4th ed. New York (NY): McGraw-Hill, 1998: 1519–34

27.

Robbins AS, Rubenstein LZ. Postural hypotension in the elderly. J Am Geriatr Soc 1984; 32: 769–74PubMed

28.

Aronow WS, Lee NH, Sales FF, et al. Prevalence of postural hypotension in elderly patients in a long-term health care facility. Am J Cardiol 1988; 62: 336PubMedCrossRef

29.

Lipsitz LA, Nyquist Jr RP, Wei JY, et al. Postprandial reduction in blood pressure in the elderly. N Engl J Med 1983; 309: 81–3PubMedCrossRef

30.

Aronow WS, Ahn C. Postprandial hypotension in 499 elderly persons in a long-term health care facility. J Am Geriatr Soc 1994; 42: 930–2PubMed

31.

Aronow WS, Ahn C. Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. J Am Geriatr Soc 1997; 45: 1051–3PubMed

32.

Aronow WS. Effects of aging on the heart. In: Tallis R, Fillit H, editors. Brocklehurst’s textbook of geriatric medicine and gerontology. 6th ed. London: Churchill Livingstone, 2003: 425–40

33.

Gribbin B, Pickering GT, Sleight P, et al. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971; 29: 424–31PubMedCrossRef

34.

Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30PubMedCrossRef

35.

Baglin A, Boulard JC, Hanslik T, et al. Metabolic adverse reactions to diuretics: clinical relevance to elderly patients. Drug Saf 1995; 12: 161–7PubMedCrossRef

36.

Sica DA, Gehr TW. Diuretic combinations in refractory edema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30: 229–49PubMedCrossRef

37.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75CrossRef

38.

Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29–35PubMedCrossRef

39.

Scott JT, Higgens CS. Diuretic-induced gout: a multi-factorial condition. Ann Rheum Dis 1992; 51: 259–61PubMedCrossRef

40.

Hunt SA, Abraham WT, Feldman AM, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. J Am Coll Cardiol 2005; 46: 1116–43CrossRef

41.

Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21PubMedCrossRef

42.

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17PubMedCrossRef

43.

Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol 2001; 87: 780–1PubMedCrossRef

44.

Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001; 87: 1284–6PubMedCrossRef

45.

Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001; 88: 1298–300PubMedCrossRef

46.

Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994; 74: 674–80PubMedCrossRef

47.

Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994; 74: 267–70PubMedCrossRef

48.

MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet 1999; 353: 2001–7CrossRef

49.

Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus non-fatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol 1997; 80: 207–9PubMedCrossRef

50.

Aronow WS, Frishman WH. Angina in the elderly. In: Aronow WS, Fleg JL, Rich MW editors. Cardiovascular disease in the elderly. 4th ed. New York: Informa Healthcare, 2008: 269–92CrossRef

51.

Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994; 74: 613–5PubMedCrossRef

52.

Aronow WS. Treatment of atrial fibrillation: part 1. Cardiol Rev 2008; 16: 181–8PubMedCrossRef

53.

Aronow WS. Treatment of atrial fibrillation and atrial flutter part 2. Cardiol Rev 2008; 16: 230–9PubMedCrossRef

54.

Aronow WS. The heart and thyroid disease. In: Gambert SR, editor. Clinics in geriatric medicine: thyroid disease. Philadelphia (PA): W B Saunders, 1995: 219–29

55.

Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761–88PubMedCrossRef

56.

Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–28PubMedCrossRef

57.

Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9PubMedCrossRef

58.

The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59CrossRef

59.

Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234–42PubMed

60.

Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256–61PubMedCrossRef

61.

Hricick DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373–6CrossRef

62.

Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin-converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115: 513–9PubMed

63.

Pahor M, Guralnik JM, Corti C, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191–7PubMed

64.

Aronow WS. Verapamil as an antiarrhythmic agent. In: Gould LA, editor. Drug treatment of cardiac arrhythmias. Mount Kisco (NY): Futura Publishing Company, 1983: 325–41

65.

The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92CrossRef

66.

Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52–60PubMedCrossRef

67.

Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002; 89: 1207–9PubMedCrossRef

68.

Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954–61PubMedCrossRef

69.

Lewis JG. Adverse reactions to calcium antagonists. Drugs 1983; 25: 196–222PubMedCrossRef

70.

Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14PubMedCrossRef

71.

Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation 1997; 96: 856–63PubMedCrossRef

72.

Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg JL, Rich MW editors. Cardiovascular disease in the elderly. 4th ed. New York: Informa Healthcare, 2008: 99–135CrossRef

73.

Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ (Clin Res Ed) 1984; 289: 410–2CrossRef

74.

Krehlik JM, Hindson DA, Crowley Jr JJ, et al. Minoxidil-associated pericarditis and fatal cardiac tamponade. West J Med 1986; 143: 527–9

Title: Treating Hypertension in Older Adults
Safety Considerations
Author: Dr Wilbert S. Aronow
Publication date: 01-02-2009
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 2/2009
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200932020-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treating Hypertension in Older Adults

Safety Considerations

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions

Examining the Tolerability of the Non-Sedating Antihistamine Desloratadine

Risk Management of Medicines and Compensation for Harm

Drug-versus-Drug Adverse Event Rate Comparisons

A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation

A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge